Geoffrey Paul Dowling

Ferring Pharmaceuticals Ltd. manufactures and produces pharmaceutical products. It offers Zomacton (somatropin) for that treatment of growth failure in children and for girl’s diagnosed with Turners syndrome; GONAPEPTYL (triptorelin), a GnRH agonist that is used for the treatment of children with central precocious puberty; Testim (testosterone gel), a hydroalcoholic topical gel; and PENTASA (mesalazine), which is used for the treatment of inflammatory bowel diseases. The company was founded in 1975 and is headquartered in Middlesex, the United Kingdom.

Ferring International Center SA develops, manufactures and markets products in the fields of urology, gynaecology and obstetrics. It also specializes in the fields of gastroenterology and endocrinology. The company was founded in 1950 and is headquartered in Saint-Prex, Switzerland.

Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom.

Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.

Tillotts Pharma AG manufactures pharmaceuticals for treatment of gastrointestinal diseases. The firm specializes in the therapy of the lower gastrointestinal tract. It offers Asacol, Entocort, Colpermin, Tillhepo and VistaPrep. The company was founded in 1986 and is headquartered in Ziefen, Switzerland.

Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom.

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.

Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom.

Esperante BV (Esperante) is a Dutch based venture capital firm which was founded by Dean Slagel in 2004. Esperante is a seed investor which invests in emerging biotechnology companies engaged in the development of novel therapeutics in areas of major unmet medical need. The firm has a portfolio of investments across France, the UK and the US. The firm provides investee companies with extended management resources, particularly in business development, as a complement to their financial contribution. They also conduct scientific and intellectual property evaluations using confidential life science industry consultants.

Ferring Holding SA operates as a holding company with interests in pharmaceutical products. The company was founded in 2000 and is headquartered in Saint-Prex, Switzerland.